A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
← catalyst calendarNCT07781345 · readout in 1,954 d
Sponsored by Eisai Limited (industry) · 4523.T — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
400estimated
Sites
3
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-24
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-31 | estimated | When the study began enrolling |
| Primary completion | 2031-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimers Disease
Intervention
- Other: No Intervention
Primary outcome
what the primary-completion date above is the date OFIncidence and Severity of ARIA-E, ARIA-H, Intracerebral Hemorrhage >1 cm in Diameter and Anaphylaxis
measured Up to 3 years
Related
4523.T · their whole pipeline · Alzheimer's Disease readouts
4523.T's other studiesmost recently updated first
- A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants Phase 1 · Completed
- A Study of E6742 in Participants With Systemic Lupus Erythematosus Phase 2 · Recruiting
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD) Phase 1 · Not yet recruiting
- A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants Phase 1 · Not yet recruiting
- A Post Authorization Registry Study of Participants Treated With LEQEMBI — · Not yet recruiting
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed